Legal Opinion
Janssen Biotech, Inc. v. Celltrion Healthcare Co.
District Court, D. Massachusetts
Decided September 28, 2016No. C.A. No. 15-10698-MLWPublishedCited by 2 opinions
1Opinion of the Court
MEMORANDUM AND ORDER
Wolf, District Judge.
This Memorandum is based on the transcript of the decision rendered orally on *279August 17, 2016, allowing defendants Cell-trion Healthcare Co., Ltd., Celltrion, Inc., and Hospira, Inc.’s (collectively “Cell-trion”) Motion for Summary Judgment of Invalidity of U.S. Patent No. 6,284,471 for Obviousness-Type Double Patenting (the “Gilead Motion”). This Memorandum adds citations, and clarifies and amplifies some language.
* * * ⅜
I. SUMMARY
Plaintiffs Janssen Biotech, Inc. and New York University, (collectively “Janssen”), are the holders of patents related to…
2Cases cited6 opinions
- Miles v. Apex Marine Corp.Supreme Court of the United States · 1990
- In Re Paolo LongiCourt of Appeals for the Federal Circuit · 1985
- Abuelhawa v. United StatesSupreme Court of the United States · 2009
- AbbVie Inc. v. Mathilda & Terrance Kennedy Institute of Rheumatology TrustCourt of Appeals for the Federal Circuit · 2014
- Gilead Sciences, Inc. v. Natco Pharma LimitedCourt of Appeals for the Federal Circuit · 2014
1 more not listed; retrieve them via the Exa API.
3Cited by2 opinions
- Novartis Pharmaceuticals Corp v. Breckenridge PharmaceuticalCourt of Appeals for the Federal Circuit · 2018
- Novartis Pharmaceuticals Corp. v. Breckenridge Pharmaceutical, Inc.District Court, D. Delaware · 2017